Home

Samit Hirawat

CIK 1781290 · EVP,Chief Med.Offr.,Drug Dev. · last filed 2026-06-12

Samit Hirawat is an EVP,Chief Med.Offr.,Drug Dev. who has filed 16 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing, for PCRX, was dated Jun 12, 2026. Across all open-market trades the lifetime net is +$402.3K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $5.4M across reported positions. 15 SEC filings were submitted jointly with MYERS SQUIBB CO BRISTOL.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.40M

Companies

2

Total Filings

16

Lifetime Open-Market Net

$402.3K

Filer Profile

Reported Address
BRISTOL-MYERS SQIUBB COMPANY
ROUTE 206 & PROVINCE LINE ROAD
PRINCETON, NJ 08543
Related Filers
MYERS SQUIBB CO BRISTOL — 15 joint filings, latest 2025-04-29
Pacira BioSciences, Inc. — 3 joint filings, latest 2026-06-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PCRX Director 6,405 $25.19 $161.3K $0 2 2026-06-12
BMY EVP,Chief Med.Offr.,Drug Dev. 83,513 $62.74 $5.24M $402.3K 14 2025-04-29

Recent Filings

16 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-12 PCRX Grant (A) +6,405 $0 EDGAR
2026-01-29 PCRX Grant (A) — $0 EDGAR
2025-04-29 BMY Buy (P) +4,250 $202.2K EDGAR
2025-03-12 BMY Mixed +15,331 -$1.01M EDGAR
2025-02-19 BMY Buy (P) +1,823 $100.0K EDGAR
2024-11-05 BMY Buy (P) +1,830 $100.1K EDGAR
2024-03-12 BMY Mixed +13,034 -$734.2K EDGAR
2023-07-05 BMY Mixed +4,570 -$306.1K EDGAR
2023-03-14 BMY Mixed +21,383 -$1.47M EDGAR
2022-07-05 BMY Mixed +4,570 -$367.8K EDGAR
Showing 1–10 of 16
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.